Active Ingredient History
Talimogene laherparepvec, sold under the brand name Imlygic, is a biopharmaceutical medication used to treat melanoma that cannot be operated on; it is injected directly into a subset of lesions which generates a systemic immune response against the recipient's cancer. The final four year analysis from the pivotal phase 3 study upon which TVEC was approved by the FDA showed a 31.5% response rate with a 16.9% complete response (CR) rate. There was also a substantial and statistically significant survival benefit in patients with earlier metastatic disease and in patients who hadn't received prior systemic treatment for melanoma. The earlier stage group had a reduction in the risk of death of approximately 50% with one in four patients appearing to have met, or be close to be reaching, the medical definition of cure. Real world use of talimogene laherparepvec have shown response rates of up to 88.5% with CR rates of up to 61.5%. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Melanoma (approved 2015)
Adenocarcinoma (Phase 2)
Adenocarcinoma, Papillary (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Basal Cell (Phase 2)
Carcinoma, Ductal (Phase 1/Phase 2)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Merkel Cell (Phase 2)
Carcinoma, Signet Ring Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 3)
Carcinoma, Transitional Cell (Phase 1)
Colorectal Neoplasms (Phase 1)
Dermatology (Phase 2)
Hamartoma (Phase 1)
Head and Neck Neoplasms (Phase 3)
Keratoacanthoma (Phase 2)
Leiomyosarcoma (Phase 2)
Liposarcoma (Phase 2)
Liver Neoplasms (Phase 1)
Lung Neoplasms (Phase 1/Phase 2)
Lymph Nodes (Phase 1)
Lymphoma (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Melanoma (Phase 3)
Mutation (Phase 2)
Mycosis Fungoides (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Neoplasms, Adnexal and Skin Appendage (Phase 2)
Paget Disease, Extramammary (Phase 2)
Pancreatic Neoplasms (Phase 1)
Pleural Effusion, Malignant (Phase 1/Phase 2)
Sarcoma (Phase 2)
Sarcoma, Kaposi (Phase 2)
Sezary Syndrome (Phase 2)
Skin Neoplasms (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Vulvar Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
